Category: Dementia

Decline in work productivity may begin years before early-onset dementia diagnosis

People who develop early-onset dementia may experience a gradual decline in work productivity up to 15 years before receiving a diagnosis, according to a new Finnish study published in Neurology. The findings highlight the substantial personal and economic impact of dementia during working age and suggest that subtle cognitive changes may affect employment long before…

FDA approves at-home subcutaneous lecanemab initiation for early Alzheimer’s disease

The US Food and Drug Administration (FDA) has approved a supplemental biologics licence application for LEQEMBI IQLIK (lecanemab-irmb) as a once-weekly subcutaneous initiation treatment for adults with early Alzheimer’s disease. The decision makes LEQEMBI IQLIK the first anti-amyloid therapy approved for both initiation and maintenance dosing at home using an autoinjector in the United States….

How gut bacteria could trigger memory loss as we age

Scientists are uncovering new evidence that changes in gut bacteria may play a direct role in age-related memory loss. A recent study published in Nature by researchers at the Arc Institute in California suggests that specific microbes in the gut could influence brain function through immune and neural pathways. The research team, led by Christoph…

Reframing dementia through design with disappearing ink

Dementia remains the leading cause of death in the UK, yet public understanding of the condition is still shaped by stigma and limited communication. A new design-led publication titled 4,4,4&2 seeks to address this gap by offering a creative, experience-based way of understanding cognitive decline through the use of disappearing ink. Developed by creative studio…

Type 1 diabetes associated with higher risk of dementia

People living with type 1 diabetes may face a significantly higher risk of developing dementia, according to new research published in Neurology, the medical journal of the American Academy of Neurology. The study highlights a growing need to better understand long term neurological outcomes in individuals with type 1 diabetes, particularly as advances in medical…

Blarcamesine Anavex marketing authorisation refused by EMA for Alzheimer’s disease

The European Medicines Agency (EMA) has recommended refusing marketing authorisation for Blarcamesine Anavex, a proposed treatment for Alzheimer’s disease, following a negative opinion adopted on 11 December 2025. The applicant company, Anavex Germany GmbH, can request a re-examination within 15 days of receiving the opinion. Blarcamesine Anavex contains blarcamesine (as blarcamesine hydrochloride) and was intended…

Dementia risk test for the NHS

Foodforthebrain.org, a UK charity focused on Alzheimer’s prevention, has been chosen by Innovate UK to develop a new test that could help the NHS identify people at risk of dementia earlier. The initiative aims to pinpoint early markers of cognitive decline so that individuals can take preventive action long before symptoms appear. Current diagnostic tools…